MiniMed Group Inc (NASDAQ:MMED) Receives $21.67 Consensus Target Price from Brokerages

MiniMed Group Inc (NASDAQ:MMED) has been given a consensus rating of “Moderate Buy” by the fourteen analysts that are currently covering the stock, Marketbeat reports. Two analysts have rated the stock with a hold rating, eleven have assigned a buy rating and one has issued a strong buy rating on the company. The average twelve-month price objective among analysts that have issued a report on the stock in the last year is $21.6667.

A number of brokerages have weighed in on MMED. Deutsche Bank Aktiengesellschaft began coverage on shares of MiniMed Group in a research report on Tuesday, March 31st. They set a “buy” rating and a $20.00 target price for the company. BTIG Research began coverage on shares of MiniMed Group in a research report on Tuesday, March 31st. They set a “buy” rating and a $25.00 target price for the company. Wells Fargo & Company began coverage on shares of MiniMed Group in a research report on Tuesday, March 31st. They set an “overweight” rating and a $26.00 target price for the company. Benchmark began coverage on shares of MiniMed Group in a research report on Tuesday, May 12th. They set a “buy” rating and a $20.00 target price for the company. Finally, Barclays began coverage on shares of MiniMed Group in a research report on Wednesday, April 1st. They set an “overweight” rating and a $26.00 target price for the company.

MiniMed Group Price Performance

MMED opened at $11.18 on Wednesday. The firm’s 50-day moving average is $13.51. MiniMed Group has a fifty-two week low of $10.65 and a fifty-two week high of $20.48.

MiniMed Group Company Profile

We are a scaled global medical technology company that develops, manufactures, and markets a comprehensive suite of solutions for the management of diabetes. Since our founding more than 40 years ago, we have pioneered groundbreaking innovation and served the needs of our customers across the globe in service of our mission to make every day a better day for people with diabetes. Today, we are the only player in the market that commercializes all parts of an integrated diabetes management system.